Background: CD133 has been identified as a putative cancer stem cell marker in colorectal
cancer (CRC). However, the clinicopathological and prognostic significance of CD133 in …

Toca 511 (vocimagene amiretrorepvec) is an investigational nonlytic, retroviral replicating
vector (RRV) that delivers a yeast cytosine deaminase, which converts subsequently …

Epigenetic alterations are one of the main factors that disrupt the expression of genes and
consequently, they have an important role in the carcinogenicity and the progression of …

This paper reports the preparation of versatile electrochemical biosensing platforms for the
simple, rapid, and PCR-independent detection of the most frequent DNA methylation marks …

Background/Objective CD133 is currently considered the most robust surface marker for
colorectal cancer stem cells. Two meta-analysis reports have suggested that CD133 …

Background Biomarkers that can predict the prognosis of colorectal cancer (CRC) patients
and that can stratify high-risk early stage patients from low-risk early stage patients are …

The marine environment is a promising source of natural products with possible
pharmacological applications. In this sense, marine microorganisms, especially marine …

Abstract Objective Approximately 42% of American adults are living with obesity, increasing
their risk of colorectal cancer (CRC). Efficacious approaches to prevent and treat obesity …

We performed a meta-analysis of CD133-related clinical data to investigate the role of
cancer stem cells (CSCs) in the clinical outcomes of colorectal cancer (CRC) patients …

Rectal cancer involves one-third of colorectal cancers (CRCs). Recently, data supported that
DNA methylation have a role in CRC pathogenesis. In the present study we aimed to …